1. Fromstein SR, Harthan JS, Patel J, et al. Demodex blepharitis: clinical perspectives. Clin. Optom. 2018;10:57–63.
2. Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311–8.
3. Farid M, Ayres BD, Donnenfeld E, et al. Delphi panel consensus regarding current clinical practice management options for Demodex blepharitis. Clin Ophthalmol. 2023;17:667–79.
4. Tarsus Pharmaceuticals. FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis [media release]. 25 Jul 2023. https://ir.tarsusrx.com/news-releases/news-release-details/fda-approves-xdemvytm-lotilaner-ophthalmic-solution-025.
5. Tarsus Pharmaceuticals. XDEMVY™ (lotilaner ophthalmic solution) 0.25%, for topical ophthalmic use: US prescribing information. 2023. https://tarsusrx.com/wp-content/uploads/XDEMVY-Prescribing-Information-24JUL23.pdf. Accessed 28 Aug 2023.